CELVIA CC AS

Their core work

Celvia CC is an Estonian private company specializing in female reproductive biology research, with deep expertise in endometriosis, uterine biology, and fertility. They contribute to EU research consortia focused on understanding molecular mechanisms of reproductive disorders, developing non-invasive diagnostic approaches, and mapping the human uterus at cellular resolution. Their work spans from basic science (stem cells, proteoglycans, microRNA) to translational applications like prenatal testing and infertility treatment strategies.

What they specialise in

How they've shifted over time

Celvia CC entered H2020 in 2016 with a focus on the molecular mechanisms of endometriosis (MOMENDO), then broadened significantly from 2019 onward into reproductive toxicology, endocrine disruptors, and biomarker screening (FREIA). Their most recent projects (2020–2021) show a shift toward translational applications — building a human uterus cell atlas (HUTER) and pursuing clinical translation of endometriosis research (TRENDO), suggesting a move from basic molecular research toward diagnostics and clinical tools.

Moving from basic reproductive biology toward translational tools — cell atlases, biomarkers, and non-invasive diagnostics — making them increasingly relevant for clinical and diagnostic industry partners.

How they like to work

Celvia CC operates exclusively as a participant or third-party partner, never coordinating projects themselves. With 35 unique consortium partners across 16 countries from just 5 projects, they consistently join large, internationally diverse research networks. This pattern suggests they are valued as a specialist contributor brought in for specific reproductive biology expertise rather than acting as a project driver.

Broadly connected across Europe with 35 unique partners in 16 countries from 5 projects, indicating they are embedded in major reproductive medicine research networks rather than working with a narrow circle of repeat collaborators.

What sets them apart

As a private SME in Estonia focused entirely on female reproductive biology, Celvia CC occupies a rare niche — most organizations in this space are university departments or hospital labs, not commercial entities. Their combination of endometriosis expertise, uterine cell biology, and involvement in both MSCA training networks and RIA research actions makes them a versatile partner who bridges academic research and commercial application. For consortium builders, they offer specialist reproductive biology know-how from an underrepresented EU-13 country, which can strengthen geographic balance in proposals.

Highlights from their portfolio

• FREIA
  Largest single grant (EUR 311,375) — a major research action on endocrine disruptor screening with direct regulatory relevance.
• HUTER
  Human Uterus Cell Atlas project (EUR 298,750) represents frontier single-cell biology applied to a largely unmapped organ.
• TRENDO
  Most recent project focusing on translational endometriosis research, signaling the company's shift toward clinical applications.